UT-HTL
14.4.2021 12:02:13 CEST | Business Wire | Press release
HTL , the worldwide leader in biotechnology solutions using hyaluronic acid (HA) and other biopolymers, and Echelon Biosciences Inc. , a U.S.-based global supplier of biochemical reagents, assays, and services to research and development laboratories, announced today their new distribution and product development partnership. The partnership will enable distribution of high-quality HA and glycosaminoglycan (GAG), and the co-development of novel GAG products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414005119/en/
The partnership provides academic research and pharmaceutical development laboratories’ expanded access to Good Manufacturing Practices (GMP)-grade, kit-packaged hyaluronic acid and glycosaminoglycan (GAG) products. By offering premium, clinical grade products to early-stage research investigators, the partnership seeks to bridge the gap between lab-based research, development and commercialization, and accelerate innovation worldwide.
“Innovation is at the heart of HTL’s DNA,” said HTL CEO Yvon Bastard . “This growth opportunity reinforces our mission and vision to apply science for increased bio-compatibility and improved health outcomes around the world.”
“This new partnership offers scientists and researchers the key technologies to develop innovative biopolymer solutions for new medical applications in aesthetics, ophthalmology, rheumatology, tissue engineering and drug delivery,” said Charles Ruban , HTL deputy CEO. “This is the true meaning of HTL’s tagline of ‘Beyond, together.’ HTL’s ambition is not only to grow its lead position in producing and distributing hyaluronic acid worldwide, but also to build tomorrow’s glycosaminoglycan-based solutions.”
“Echelon has been granted the opportunity to expand its market-leading HA assays and extra cellular matrix product line with the supply of HTL ’s hyaluronic acid and other GAG-derived products. HTL is recognized internationally for producing biopolymers of premium quality,” says Bert Israelsen , president of Echelon Biosciences . “Echelon offers our customers access to the latest innovative tools with unparalleled technical support, thereby fully enabling maximized creativity in basic and applied research. With its fermentation and organic synthesis platforms, HTL creates functionality and added value by developing chemically modified biopolymers tailored to specific needs.”
“This new partnership is a milestone in HTL’s expanding footprint in the North American market and with the U.S. medical community,” said Glenn Prestwich, Ph.D ., one of Echelon’s founders and now HTL’s exclusive science and innovation advisor for this market. By entrusting Echelon with the distribution of HTL’s hyaluronic acid and glycosaminoglycan products for research use, HTL aims to significantly increase its support and involvement in biopolymer research in the U.S. and worldwide, but also its research and development capacity.
“This new initiative demonstrates HTL’s commitment to invest in innovation in healthcare,” said Humberto C. Antunes , strategic advisor to HTL and former CEO of Galderma. “In the fields of health and wellness, the biotechnology ecosystem of innovation, incubators, and established and emerging companies are incredibly dynamic in the United States, Mexico and Canada. It means a huge growth potential for HTL products,” added Antunes.
About HTL
HTL is a biotechnology company, leading the way in the design and production of pharmaceutical grade hyaluronic acid and other innovative functional biopolymers for premium medical products. HTL serves the pharmaceutical and medical device industries worldwide, enabling them to transform lives of patients. HTL’s unsurpassed commitment to client partnership has been consistently proven in the marketplace. The company is recognized for supplying the highest quality products and continually investing in driving and supporting market growth. For over 25 years, its cutting-edge research and development has allowed to develop unique value-driven solutions to meet the innovation needs of its clients.
About Echelon Biosciences, Inc.
Based in Salt Lake City, Utah, Echelon Biosciences, was established in 1997 to supply synthetic lipid reagents for research and development. Since then, Echelon has successfully grown in scale and scope to include custom chemistry, peptides, and biological assays with over 700 catalog items in the fields of cell signaling, extracellular matrix, cancer drug discovery, and disease biomarkers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005119/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Experian Brings Trusted Agentic AI to Financial Services With the Launch of Agent Operating System™2.6.2026 15:05:00 CEST | Press release
A new core capability within Experian’s Ascend Platform, designed to help financial services organisations safely scale agentic AI across the lending lifecycleBrings together Experian, client and partner AI agents within a trusted operating layer for data, decisioning, governance and control55% of consumers say they would allow an AI agent to make an autonomous purchase on their behalfServiceNow becomes first partner to integrate with Experian’s Agent Operating System Experian today announces the launch of the Agent Operating System™, a trusted agentic AI layer within the Experian Ascend Platform, unveiled at Money20/20 Europe. The Experian Agent Operating System is designed to help financial services organisations move successfully beyond AI experimentation and safely scale agentic AI to transform decision-making, customer experiences, and day-to-day operations. It enables AI agents from Experian, clients and partners to work together through a common trust, semantic and orchestration
Lenovo Technology Powers FIFA World Cup 2026™ Operations and Strengthens AI-Driven Broadcast2.6.2026 15:00:00 CEST | Press release
Lenovo’s Near Real-Time AI Infrastructure Enables IPTV Delivery, Operational Control, and Transformative Fan Experiences at Unprecedented Global Scale Lenovo today announced it is delivering a near real-time AI-powered infrastructure platform for the FIFA World Cup 2026™ to enable ultra-low-latency IPTV (Internet Protocol Television) video distribution in addition to the traditional cable and satellite broadcast, intelligent content delivery, and mission-critical decision-making across the event ecosystem and operations. As the world’s largest sporting event prepares for an unprecedented scale—spanning three host countries, featuring 48 teams, and engaging an estimated 6 billion fans—FIFA, broadcasters, and event operators will benefit from a live, always-on environment designed to perform at the highest level. As FIFA’s Official Technology Partner, Lenovo will deploy servers at the International Broadcast Center in Dallas, Texas, to help deliver the computing power, devices, and AI-dr
High Q Technologies and Creative Biostructure Announce Strategic Partnership Expanding Global Access to Quantum-Enabled EPR Spectroscopy2.6.2026 15:00:00 CEST | Press release
Collaboration Aims to Accelerate Adoption of EPR Spectroscopy in Structural Biology and Drug Discovery High Q Technologies, a developer of quantum-enabled electron paramagnetic resonance (EPR) spectroscopy systems, and Creative Biostructure, a structural biology Contract Research Organization, today announced a strategic partnership to support broader adoption of EPR spectroscopy for studying protein dynamics in pharmaceutical and biotechnology research. EPR spectroscopy is increasingly relevant as drug discovery turns toward disordered, flexible, and disease‑relevant protein systems that cannot be fully understood through static structural methods alone. However, broad adoption of EPR has historically been limited by instrument and workflow complexity, and the need for dedicated technical expertise in experimental design and data interpretation. Leveraging quantum sensor technology, FATHOM® EPR has overcome these challenges. By providing unique measurements of long‑range distances, FA
New Tacton Research Reveals Only 7% of Manufacturers Have Achieved End-to-End Value Chain Connectivity2.6.2026 15:00:00 CEST | Press release
Despite growing digital maturity and AI investment, less than half of manufacturers are confident in their ability to deliver effectively on their sales promise to customers. Tacton, a global leader in Configure, Price, Quote (CPQ) solutions for manufacturers of complex, highly configurable products, today released its annual State of Manufacturing report, revealing that rising product complexity is exposing critical cross-functional gaps despite continued investment in digital transformation and AI. Based on a survey of 280 manufacturing leaders in eight countries, the research found that 67% now describe their products as “very” or “extremely” complex, a 20-point increase in just one year. At the same time, only 7% use the same product configuration rules across every team and system involved in selling and building products, which is critical for reducing margin risk because of siloed functions and data. The report highlights a growing industry reality: while digital transformation
HTEC and Xsolis’ Strategic Partnership to Tackle Inefficiencies in Healthcare Decision-Making with AI2.6.2026 14:38:00 CEST | Press release
Collaboration will accelerate the evolution of Xsolis’ Dragonfly platform, improving how healthcare providers and payers make faster, more aligned care decisions HTEC, the global AI-first engineering and digital product development company, today announced a strategic partnership with Xsolis, an AI-driven technology company that reduces administrative waste by enabling collaboration between healthcare providers and payers. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260602462348/en/ HTEC, the global AI-first engineering and digital product development company, today announced a strategic partnership with Xsolis, an AI-driven technology company that reduces administrative waste by enabling collaboration between healthcare providers and payers. Across healthcare systems, determining whether a treatment is medically necessary, what level of care a patient requires, and whether that care will be approved remains a slow, manua
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom